Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
2 "Joong-Bae Ahn"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea
Min Hee Hong, Hyo Song Kim, Chan Kim, Jung Ryun Ahn, Hong Jae Chon, Sang-Joon Shin, Joong-Bae Ahn, Hyun Cheol Chung, Sun Young Rha
Cancer Res Treat. 2009;41(2):67-72.   Published online June 30, 2009
DOI: https://doi.org/10.4143/crt.2009.41.2.67
AbstractAbstract PDFPubReaderePub
Purpose

The retrospective study was performed to assess the efficacy and toxicity profiles of sunitinib in Korean patients with metastatic renal cell carcinoma (RCC).

Materials and Methods

Between January 2005 and December 2008, 76 Korean patients with recurrent/metastatic RCC who received sunitinib were retrospectively reviewed. The primary end point was progression-free survival and the secondary end points were overall survival and response rate. We also assessed the toxicities associated with sunitinib treatment.

Results

Of the 76 patients, 69 (90.1%) were diagnosed with clear cell RCC. The median progression-free survival and overall survival were 7.2 and 22.8 months, respectively in overall patients. Sixty-two patients (81.6%) received 50 mg 4 week and 2 week off schedule, and 14 patients (18.4%) received 37.5 mg daily on a daily continuous schedule. The objective response rate and disease control rate were 27.6% and 84.2%, respectively. A dose reduction or reduction in dose due to adverse events occurred in 76% of the patients, whereas 11% of the patients had discontinued treatment. Other common laboratory abnormalities were increased serum creatinine (75.6%), elevated alanine aminotransferase (71.0%), neutropenia (61.8%), anemia (69.7%), and increased aspartate aminotrasferase (53.3%). Grade 3/4 toxicities occurred as follows: thrombocytopenia (38.2%), fatigue (10.5%), stomatitis (10.5%), and hand-foot syndrome (9.2%).

Conclusion

Our results indicate that sunitinib treatment is effective and tolerable for ecurrent/metastatic RCC patients in Korea. Further studies with prognostic or biochemical factors are needed to clarify the different toxicity profiles of this study.

Citations

Citations to this article as recorded by  
  • pH-Responsive Block Copolymer Micelles of Temsirolimus: Preparation, Characterization and Antitumor Activity Evaluation
    Ling Wang, Fangqing Cai, Yixuan Li, Xiaolan Lin, Yuting Wang, Weijie Liang, Caiyu Liu, Cunze Wang, Junshan Ruan
    International Journal of Nanomedicine.2024; Volume 19: 9821.     CrossRef
  • Comparative Evaluation of Safety and Efficacy of Alternate Schedule (AS) of Sunitinib in Asian and Non-Asian Patient Population for the Treatment of Metastatic Renal Cell Cancer (mRCC): A Meta-Analysis
    Amit Joshi, Ishan Patel, Pratiksha Kapse, Manmohan Singh
    Kidney Cancer.2022; 6(1): 37.     CrossRef
  • High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma
    Yun Beom Sang, Hannah Yang, Won Suk Lee, Seung Joon Lee, Seul-Gi Kim, Jaekyung Cheon, Beodeul Kang, Chang Woo Kim, Hong Jae Chon, Chan Kim
    Cancers.2022; 14(23): 5985.     CrossRef
  • Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma
    Dongrul Shin, Chang Wook Jeong, Cheryn Song, Minyong Kang, Seong Il Seo, Jung Kwon Kim, Hakmin Lee, Jinsoo Chung, Sung-Hoo Hong, Eu Chang Hwang, Cheol Kwak, Jae Young Park
    Medicine.2021; 100(31): e26826.     CrossRef
  • Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population
    Ahmed Badran, Mahmoud A. Elshenawy, Amgad Shahin, Ali Aljubran, Ahmed Alzahrani, Abdelmoneim Eldali, Shouki Bazarbashi
    JCO Global Oncology.2020; (6): 19.     CrossRef
  • Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101
    Motohide Uemura, Yoshihiko Tomita, Hideaki Miyake, Shingo Hatakeyama, Hiro‐omi Kanayama, Kazuyuki Numakura, Toshio Takagi, Tomoyuki Kato, Masatoshi Eto, Wataru Obara, Hirotsugu Uemura, Toni K. Choueiri, Robert J. Motzer, Yosuke Fujii, Yoichi Kamei, Yoshik
    Cancer Science.2020; 111(3): 907.     CrossRef
  • First-Line Axitinib Versus Sorafenib in Asian Patients with Metastatic Renal Cell Carcinoma: Exploratory Subgroup Analyses of Phase III Data
    Xinan Sheng, Feng Bi, Xiubao Ren, Ying Cheng, Jinwan Wang, Brad Rosbrook, Ming Jiang, Jun Guo
    Future Oncology.2019; 15(1): 53.     CrossRef
  • The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics
    Hiu Ting Chan, Yoon Ming Chin, Siew-Kee Low
    Oncology and Therapy.2019; 7(1): 1.     CrossRef
  • Risk of fatal adverse events in cancer patients treated with sunitinib
    Bin Zhao, Hong Zhao, Jiaxin Zhao
    Critical Reviews in Oncology/Hematology.2019; 137: 115.     CrossRef
  • Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
    Jii Bum Lee, Hyung Soon Park, Sejung Park, Hyo Jin Lee, Kyung A Kwon, Young Jin Choi, Yu Jung Kim, Chung Mo Nam, Nam Hoon Cho, Beodeul Kang, Hyun Cheol Chung, Sun Young Rha
    Cancer Research and Treatment.2019; 51(4): 1578.     CrossRef
  • Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients
    Claudia Arena, Giuseppe Troiano, Alfredo De Lillo, Nunzio F. Testa, Lorenzo Lo Muzio
    BioMed Research International.2018; 2018: 1.     CrossRef
  • Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma
    Nahjatul Kursyiah Abd Ghafar, Adlinda Alip, Teng Aik Ong, Ning Yi Yap, Marniza Saad
    Journal of Cancer Research and Therapeutics.2018; 14(6): 1303.     CrossRef
  • Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis
    Xiaoyan Liu, Marta Fiocco, Jesse J. Swen, Henk-Jan Guchelaar
    Acta Oncologica.2017; 56(4): 582.     CrossRef
  • Oncogenic miR-100-5p is associated with cellular viability, migration and apoptosis in renal cell carcinoma
    Peijie Chen, Canbin Lin, Jing Quan, Yulin Lai, Tao He, Liang Zhou, Xiang Pan, Xueling Wu, Yong Wang, Liangchao Ni, Shangqi Yang, Tao Wang, Yongqing Lai
    Molecular Medicine Reports.2017; 16(4): 5023.     CrossRef
  • miR‑660‑5p is associated with cell migration, invasion, proliferation and apoptosis in renal cell carcinoma
    Tao He, Peijie Chen, Lu Jin, Jia Hu, Yifan Li, Liang Zhou, Shangqi Yang, Xiangming Mao, Yaoting Gui, Yun Chen, Yongqing Lai
    Molecular Medicine Reports.2017;[Epub]     CrossRef
  • Synergistic Survival: A New Phenomenon Connected to Adverse Events of First-Line Sunitinib Treatment in Advanced Renal Cell Carcinoma
    Krisztián Nagyiványi, Barna Budai, Krisztina Bíró, Fruzsina Gyergyay, László Noszek, Zsófia Küronya, Hajnalka Németh, Péter Nagy, Lajos Géczi
    Clinical Genitourinary Cancer.2016; 14(4): 314.     CrossRef
  • BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen
    Jung-woo Chae, Yi Ling Teo, Han Kiat Ho, Jaeyeon Lee, Hyun-moon Back, Hwi-yeol Yun, Mats O. Karlsson, Kwang-il Kwon, Alexandre Chan
    Cancer Chemotherapy and Pharmacology.2016; 78(3): 623.     CrossRef
  • Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study
    Yoshihiko Tomita, Satoshi Fukasawa, Mototsugu Oya, Hirotsugu Uemura, Nobuo Shinohara, Tomonori Habuchi, Brian I. Rini, Ying Chen, Angel H. Bair, Seiichiro Ozono, Seiji Naito, Hideyuki Akaza
    Japanese Journal of Clinical Oncology.2016; 46(11): 1031.     CrossRef
  • Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction
    Siew-Kee Low, Koya Fukunaga, Atsushi Takahashi, Koichi Matsuda, Fumiya Hongo, Hiroyuki Nakanishi, Hiroshi Kitamura, Takamitsu Inoue, Yoichiro Kato, Yoshihiko Tomita, Satoshi Fukasawa, Tomoaki Tanaka, Kazuo Nishimura, Hirotsugu Uemura, Isao Hara, Masato Fu
    PLOS ONE.2016; 11(2): e0148177.     CrossRef
  • Sunitinib therapy for metastatic renal cell carcinoma: A urologist’s perspective
    M Darrad, R Wilson
    Journal of Clinical Urology.2016; 9(1): 32.     CrossRef
  • Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience
    Rafael Corrêa Coelho, Tomás Reinert, Franz Campos, Fábio Affonso Peixoto, Carlos Augusto de Andrade, Thalita Castro, Daniel Herchenhorn
    International braz j urol.2016; 42(4): 694.     CrossRef
  • Tumor suppressor miR-149-5p is associated with cellular migration, proliferation and apoptosis in renal cell carcinoma
    LU JIN, YIFAN LI, JIAJU LIU, SHANGQI YANG, YAOTING GUI, XIANGMING MAO, GUOHUI NIE, YONGQING LAI
    Molecular Medicine Reports.2016; 13(6): 5386.     CrossRef
  • Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore
    Hui Shan Tan, Huihua Li, Yu Wen Hong, Chee-Keong Toh, Alvin Wong, Gilberto Lopes, Miah Hiang Tay, Alexandre Chan, Xin Yao, Tiffany Tang, Quan Sing Ng, Ravindran Kanesvaran, Noan Minh Chau, Min-Han Tan
    Clinical Genitourinary Cancer.2015; 13(4): e285.     CrossRef
  • Central and Eastern European Experience with Sunitinib in Metastatic Renal Cell Carcinoma: A Sub-analysis of the Global Expanded-Access Trial
    Eduard Vrdoljak, Lajos Géczi, Jozef Mardiak, Tudor-Eliade Ciuleanu, Sophie Leyman, Ke Zhang, Peter Sajben, Laszlo Torday
    Pathology & Oncology Research.2015; 21(3): 775.     CrossRef
  • Axitinib plasma pharmacokinetics and ethnic differences
    Ying Chen, Akiyuki Suzuki, Michael A. Tortorici, May Garrett, Robert R. LaBadie, Yoshiko Umeyama, Yazdi K. Pithavala
    Investigational New Drugs.2015; 33(2): 521.     CrossRef
  • Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors
    Tomohiro Terada, Satoshi Noda, Ken-ichi Inui
    Pharmacology & Therapeutics.2015; 152: 125.     CrossRef
  • RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial
    J.L. Lee, M.K. Kim, I. Park, J.-H. Ahn, D.H. Lee, H.M. Ryoo, C. Song, B. Hong, J.H. Hong, H. Ahn
    Annals of Oncology.2015; 26(11): 2300.     CrossRef
  • Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer
    Naomi Kiyota, Martin Schlumberger, Kei Muro, Yuichi Ando, Shunji Takahashi, Yasukazu Kawai, Lori Wirth, Bruce Robinson, Steven Sherman, Takuya Suzuki, Katsuki Fujino, Anubha Gupta, Seiichi Hayato, Makoto Tahara
    Cancer Science.2015; 106(12): 1714.     CrossRef
  • Efficacy and Toxicity of Sunitinib in Metastatic Renal Cell Carcinoma Patients in Egypt
    Wael Abdelgawad Edesa, Raafat Ragaey Abdelmalek
    Asian Pacific Journal of Cancer Prevention.2015; 16(5): 1971.     CrossRef
  • Induction of apoptotic cell death by betulin in multidrug-resistant human renal carcinoma cells
    NAM-HUI YIM, YOUNG PIL JUNG, AEYUNG KIM, TAESOO KIM, JIN YEUL MA
    Oncology Reports.2015; 34(2): 1058.     CrossRef
  • Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients
    Y Wang, T K Choueiri, J-L Lee, M-H Tan, S Y Rha, S A North, C K Kollmannsberger, D F McDermott, D Y C Heng
    British Journal of Cancer.2014; 110(6): 1433.     CrossRef
  • The Effect of ABCG2 Genotype on the Population Pharmacokinetics of Sunitinib in Patients With Renal Cell Carcinoma
    Tomoyuki Mizuno, Masahide Fukudo, Tsuyoshi Fukuda, Tomohiro Terada, Min Dong, Tomomi Kamba, Toshinari Yamasaki, Osamu Ogawa, Toshiya Katsura, Ken-ichi Inui, Alexander A. Vinks, Kazuo Matsubara
    Therapeutic Drug Monitoring.2014; 36(3): 310.     CrossRef
  • Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma
    Ibrahim Yildiz, Fatma Sen, Leyla Kilic, Rumeysa Ciftci, Mert Basaran
    Korean Journal of Urology.2014; 55(1): 74.     CrossRef
  • Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first‐line sunitinib: a medical chart review across ten centers in five European countries
    Camillo Porta, Antonin Levy, Robert Hawkins, Daniel Castellano, Joaquim Bellmunt, Paul Nathan, Ray McDermott, John Wagstaff, Paul Donnellan, John McCaffrey, Francis Vekeman, Maureen P. Neary, Jose Diaz, Faisal Mehmud, Mei Sheng Duh
    Cancer Medicine.2014; 3(6): 1517.     CrossRef
  • Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review
    WILLIAM K. OH, DAVID McDERMOTT, CAMILLO PORTA, ANTONIN LEVY, REZA ELAIDI, FLORIAN SCOTTE, ROBERT HAWKINS, DANIEL CASTELLANO, JOAQUIM BELLMUNT, SUN YOUNG RHA, JONG-MU SUN, PAUL NATHAN, BRUCE A. FEINBERG, JEFFREY SCOTT, RAY McDERMOTT, JIN-HEE AHN, JOHN WAGS
    International Journal of Oncology.2014; 44(1): 5.     CrossRef
  • Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
    R J Motzer, B Escudier, R Bukowski, B I Rini, T E Hutson, C H Barrios, X Lin, K Fly, E Matczak, M E Gore
    British Journal of Cancer.2013; 108(12): 2470.     CrossRef
  • Therapy management with sunitinib in patients with metastatic renal cell carcinoma: Key concepts and the impact of clinical biomarkers
    Daniel Castellano, Alain Ravaud, Manuela Schmidinger, Guillermo De Velasco, Federico Vazquez
    Cancer Treatment Reviews.2013; 39(3): 230.     CrossRef
  • Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients
    Hye Ryun Kim, Hyung Soon Park, Woo Sun Kwon, Ji Hyun Lee, Yusuke Tanigawara, Sun Min Lim, Hyo Song Kim, Sang Jun Shin, Jung Bae Ahn, Sun Young Rha
    Cancer Chemotherapy and Pharmacology.2013; 72(4): 825.     CrossRef
  • Validation of the MSKCC and Heng Risk Criteria Models for Predicting Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib
    Whi-An Kwon, In-Chang Cho, Ami Yu, Byung-Ho Nam, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
    Annals of Surgical Oncology.2013; 20(13): 4397.     CrossRef
  • Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma
    Ki Hyang Kim, Sang Hyun Yoon, Hae-Jung Lee, Hyo Song Kim, Sang Joon Shin, Joong Bae Ahn, Sun Young Rha
    Cancer Chemotherapy and Pharmacology.2013; 72(4): 853.     CrossRef
  • Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain
    Daniel Castellano, Mei Sheng Duh, Caroline Korves, Ellison Dial Suthoff, Maureen Neary, Luis Javier Hernández Pastor, Joaquim Bellmunt
    Expert Opinion on Drug Safety.2013; 12(4): 455.     CrossRef
  • Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib
    Aiping Zhou, Wen Zhang, Chunxiao Chang, Xiaoyan Chen, Dafang Zhong, Qiong Qin, Donghua Lou, Haoyuan Jiang, Jinwan Wang
    Cancer Chemotherapy and Pharmacology.2013; 72(5): 1043.     CrossRef
  • Analysis of the Reasons for Dose Reduction or Discontinuation of Sunitinib in Korean Patients
    노지혜, 이주연, 이혜숙, 김향숙, 강래영, 이용화
    Journal of Korean Society of Health-System Pharmacists.2013; 30(3): 210.     CrossRef
  • Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Pharmacokinetics of Sunitinib in Rats
    Sachiko Kunimatsu, Tomoyuki Mizuno, Masahide Fukudo, Toshiya Katsura
    Drug Metabolism and Disposition.2013; 41(8): 1592.     CrossRef
  • Famitinib in metastatic renal cell carcinoma: a single center study
    Wen ZHANG, Ai-Ping ZHOU, Qiong QIN, Chun-Xiao CHANG, Hao-Yuan JIANG, Jian-Hui MA, Jin-Wan WANG
    Chinese Medical Journal.2013; 126(22): 4277.     CrossRef
  • Management of sunitinib adverse events in renal cell carcinoma patients: The Asian experience
    Aiping ZHOU
    Asia-Pacific Journal of Clinical Oncology.2012; 8(2): 132.     CrossRef
  • Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients
    Dok Hyun Yoon, Min-Hee Ryu, Baek-Yeol Ryoo, Moyeol Beck, Dae Ro Choi, Yoojin Cho, Jae-Lyun Lee, Heung-Moon Chang, Tae Won Kim, Yoon-Koo Kang
    Investigational New Drugs.2012; 30(2): 819.     CrossRef
  • Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma
    In-Chang Cho, Jinsoo Chung
    Korean Journal of Urology.2012; 53(4): 217.     CrossRef
  • Impact of Genetic Variation in Breast Cancer Resistance Protein (BCRP/ABCG2) on Sunitinib Pharmacokinetics
    Tomoyuki Mizuno, Masahide Fukudo, Tomohiro Terada, Tomomi Kamba, Eijiro Nakamura, Osamu Ogawa, Ken-ichi Inui, Toshiya Katsura
    Drug Metabolism and Pharmacokinetics.2012; 27(6): 631.     CrossRef
  • Response Rates and Adverse Effects of Continuous Once-daily Sunitinib in Patients with Advanced Renal Cell Carcinoma: A Single-center Study in Turkey
    I. Yildiz, F. Sen, M. Basaran, M. Ekenel, F. Agaoglu, E. Darendeliler, H. M. Tunc, F. Ozcan, S. Bavbek
    Japanese Journal of Clinical Oncology.2011; 41(12): 1380.     CrossRef
  • Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma
    Yoshihiko Tomita, Hirotsugu Uemura, Hiroyuki Fujimoto, Hiro-omi Kanayama, Nobuo Shinohara, Hayakazu Nakazawa, Keiji Imai, Yoshiko Umeyama, Seiichiro Ozono, Seiji Naito, Hideyuki Akaza
    European Journal of Cancer.2011; 47(17): 2592.     CrossRef
  • Efficacy and Safety of Sunitinib on Metastatic Renal Cell Carcinoma: A Single-Institution Experience
    Eugene Hwang, Hyo Jin Lee, Chong Koo Sul, Jae Sung Lim
    Korean Journal of Urology.2010; 51(7): 450.     CrossRef
  • Kidney Cancer Working Group Report
    S. Naito, Y. Tomita, S. Y. Rha, H. Uemura, M. Oya, H. Z. Song, L. H. Zhong, M. I. B. A. Wahid
    Japanese Journal of Clinical Oncology.2010; 40(Supplement): i51.     CrossRef
  • Hematologic Toxicity in Patients Treated with Sunitinib for Advanced Thyroid Cancer
    Anastasios Gkountouvas, Ifigeneia Kostoglou-Athanassiou, Eirini Veniou, Panagiotis Repousis, Nikolaos Ziras, Philippos Kaldrimidis
    Thyroid.2010; 20(6): 597.     CrossRef
  • The Efficacy and Safety of Sunitinib in Korean Patients with Advanced Renal Cell Carcinoma: High Incidence of Toxicity Leads to Frequent Dose Reduction
    C. Yoo, J. E. Kim, J.-L. Lee, J.-H. Ahn, D. H. Lee, J.-S. Lee, S. Na, C.-S. Kim, J. H. Hong, B. Hong, C. Song, H. Ahn
    Japanese Journal of Clinical Oncology.2010; 40(10): 980.     CrossRef
  • Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis
    Sang Hyun Yoon, Ki Hyang Kim, Junjeong Choi, Gun Min Kim, Joo Hoon Kim, Hyo Song Kim, Young Nyun Park, Sun Young Rha
    Cancer Research and Treatment.2010; 42(3): 180.     CrossRef
  • Comparative Analysis between Immunochemotherapy and Target Therapy for Metastatic Renal Cell Carcinoma: Overview of Treatment-Related Adverse Events and the Dropout Rate in Korea
    Jee Han Lee, Sung-Goo Chang, Seung Hyun Jeon, Gyeong Eun Min, Koo Han Yoo
    Korean Journal of Urology.2010; 51(6): 379.     CrossRef
  • 12,553 View
  • 74 Download
  • 57 Crossref
Close layer
Single Immunochemical Fecal Occult Blood Test for Detection of Colorectal Neoplasia
Dae Kyung Sohn, Seung-Yong Jeong, Hyo Seong Choi, Seok-Byung Lim, Jin Myeong Huh, Dae-Hyun Kim, Dae Yong Kim, Young Hoon Kim, Hee Jin Chang, Kyung Hae Jung, Joong-Bae Ahn, Hyun Kyung Kim, Jae-Gahb Park
Cancer Res Treat. 2005;37(1):20-23.   Published online February 28, 2005
DOI: https://doi.org/10.4143/crt.2005.37.1.20
AbstractAbstract PDFPubReaderePub
Purpose

This study was designed to investigate the validity of a single immunochemical fecal occult blood test (FOBT) for detection of colorectal neoplasia.

Materials and Methods

A total of 3,794 average-risk screenees and 304 colorectal cancer patients admitted to the National Cancer Center, Korea, between May 2001 and November 2002, were studied prospectively. All screenees and admitted patients underwent FOBT and total colonoscopic examinations. Stools were self-collected, and examined using an immunochemical fecal occult blood test (OC-hemodia®, Eiken Chemical Co. Tokyo, Japan) and an OC-sensor analyzer® (Eiken Chemical Co. Tokyo, Japan).

Results

Of the 3,794 asymptomatic screenees, the colonoscopy identified colorectal adenomas and cancers in 613 (16.2%) and 12 (0.3%) subjects, respectively. The sensitivities of a single immunochemical FOBT for detecting colorectal cancers and adenomas in screenees were 25.0 and 2.4%, respectively. The false positive rate of FOBT for colorectal cancer in screenees was 1.19%. For the total 316 colorectal cancer cases (including 12 cases from screenees), the FOBT sensitivities according to the T-stage were 38.5, 75.0%, 78.9 and 79.2% for T1, 2, 3 and 4 cancers, respectively. The sensitivities according to the Dukes stages A, B and C were 63.4, 79.3 and 78.6%, respectively.

Conclusion

The sensitivities of a single immunochemical FOBT for detecting colorectal cancers and adenomas in screenees were 25.0 and 2.4%, respectively. The sensitivities of FOBT were about 80% for Dukes B or C colorectal cancers and 63.4% for Dukes A.

Citations

Citations to this article as recorded by  
  • Findings in the distal and proximal colon in colonoscopy screening after positive FIT and related pre-procedure factors
    M.� Henar Núñez Rodríguez, Pilar Díez Redondo, Fausto Riu Pons, Marta Cimavilla, Andrea Loza, Manuel Perez-Miranda
    Revista Española de Enfermedades Digestivas.2022;[Epub]     CrossRef
  • Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals
    Esmée J Grobbee, Pieter HA Wisse, Eline H Schreuders, Aafke van Roon, Leonie van Dam, Ann G Zauber, Iris Lansdorp-Vogelaar, Wichor Bramer, Sarah Berhane, Jonathan J Deeks, Ewout W Steyerberg, Monique E van Leerdam, Manon CW Spaander, Ernst J Kuipers
    Cochrane Database of Systematic Reviews.2022;[Epub]     CrossRef
  • Potential Modifiers and Different Cut-offs in Diagnostic Accuracy of Fecal Immunochemical Test in Detecting Advanced Colon Neoplasia: A Diagnostic Test Accuracy Meta-analysis
    Mohammad Yaghoobi, Parsa Mehraban Far, Lawrence Mbuagbaw, Yuhong Yuan, David Armstrong, Lehana Thabane, Paul Moayyedi
    Middle East Journal of Digestive Diseases.2022; 14(4): 382.     CrossRef
  • Guidelines for accreditation of endoscopy units: quality measures from the Korean Society of Coloproctology
    Rumi Shin, Seongdae Lee, Kyung-Su Han, Dae Kyung Sohn, Sang Hui Moon, Dong Hyun Choi, Bong-Hyeon Kye, Hae-Jung Son, Sun Il Lee, Sumin Si, Won-Kyung Kang
    Annals of Surgical Treatment and Research.2021; 100(3): 154.     CrossRef
  • Screening for Colorectal Cancer
    Jennifer S. Lin, Leslie A. Perdue, Nora B. Henrikson, Sarah I. Bean, Paula R. Blasi
    JAMA.2021; 325(19): 1978.     CrossRef
  • Colorectal Cancer Screening Outcomes of 2412 Prostate Cancer Patients Considered for Carbon Ion Radiotherapy
    Nao Kobayashi, Takahiro Oike, Nobuteru Kubo, Yuhei Miyasaka, Tatsuji Mizukami, Hiro Sato, Akiko Adachi, Hiroyuki Katoh, Hidemasa Kawamura, Tatsuya Ohno
    Cancers.2021; 13(17): 4481.     CrossRef
  • Evaluation of the Cut-Off Value of Fecal Immunochemical Test for Colorectal Cancer Screening during Health Checkups
    Hye-Ran Park, Eun-Hee Nah, Jong-Seon Lee, Seon Cho
    Journal of Laboratory Medicine and Quality Assurance.2021; 43(4): 190.     CrossRef
  • Stage-Specific Sensitivity of Fecal Immunochemical Tests for Detecting Colorectal Cancer: Systematic Review and Meta-Analysis
    Tobias Niedermaier, Yesilda Balavarca, Hermann Brenner
    American Journal of Gastroenterology.2020; 115(1): 56.     CrossRef
  • Sensitivity of Fecal Immunochemical Test for Colorectal Cancer Detection Differs According to Stage and Location
    Tobias Niedermaier, Kaja Tikk, Anton Gies, Stefanie Bieck, Hermann Brenner
    Clinical Gastroenterology and Hepatology.2020; 18(13): 2920.     CrossRef
  • Performance Characteristics of Fecal Immunochemical Tests for Colorectal Cancer and Advanced Adenomatous Polyps
    Thomas F. Imperiale, Rachel N. Gruber, Timothy E. Stump, Thomas W. Emmett, Patrick O. Monahan
    Annals of Internal Medicine.2019; 170(5): 319.     CrossRef
  • Effect of Sex, Age, and Positivity Threshold on Fecal Immunochemical Test Accuracy: A Systematic Review and Meta-analysis
    Kevin Selby, Emma H. Levine, Cecilia Doan, Anton Gies, Hermann Brenner, Charles Quesenberry, Jeffrey K. Lee, Douglas A. Corley
    Gastroenterology.2019; 157(6): 1494.     CrossRef
  • Quantitative fecal immunochemical tests for colorectal cancer screening
    Anton Gies, Megha Bhardwaj, Christian Stock, Petra Schrotz‐King, Hermann Brenner
    International Journal of Cancer.2018; 143(2): 234.     CrossRef
  • Prevalence of functional gastrointestinal disorders in adults with systemic lupus erythematosus
    M García-Carrasco, C Mendoza-Pinto, M A Autrán-Limón, E Herrera Robles, S Méndez Martínez, I Etchegaray Morales, Á Montiel Jarquín, J L Gálvez Romero, P Soto-Santillán, J Galindo-Herrera, A López-Colombo
    Lupus.2018; 27(5): 788.     CrossRef
  • Quality Metrics of a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program in Korea
    Dae Ho Kim, Jae Myung Cha, Min Seob Kwak, Jin Young Yoon, Young-Hak Cho, Jung Won Jeon, Hyun Phil Shin, Kwang Ro Joo, Joung Il Lee
    Gut and Liver.2018; 12(2): 183.     CrossRef
  • Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer
    Douglas J. Robertson, Jeffrey K. Lee, C. Richard Boland, Jason A. Dominitz, Francis M. Giardiello, David A. Johnson, Tonya Kaltenbach, David Lieberman, Theodore R. Levin, Douglas K. Rex
    Gastroenterology.2017; 152(5): 1217.     CrossRef
  • Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer
    Douglas J. Robertson, Jeffrey K. Lee, C. Richard Boland, Jason A. Dominitz, Francis M. Giardiello, David A. Johnson, Tonya Kaltenbach, David Lieberman, Theodore R. Levin, Douglas K. Rex
    Gastrointestinal Endoscopy.2017; 85(1): 2.     CrossRef
  • Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer
    Douglas J Robertson, Jeffrey K Lee, Richard C Boland, Jason A Dominitz, Francis M Giardiello, David A Johnson, Tonya Kaltenbach, David Lieberman, Theodore R Levin, Douglas K Rex
    American Journal of Gastroenterology.2017; 112(1): 37.     CrossRef
  • Risk Factors for False Fecal Immunochemical Test Results in Colorectal Cancer Screening
    Nam Hee Kim, Jung Ho Park, Dong Il Park, Chong Il Sohn, Kyuyong Choi, Yoon Suk Jung
    Journal of Clinical Gastroenterology.2017; 51(2): 151.     CrossRef
  • Which Fecal Immunochemical Test Should I Choose?
    Jeanette M. Daly, Yinghui Xu, Barcey T. Levy
    Journal of Primary Care & Community Health.2017; 8(4): 264.     CrossRef
  • Cancer-Type Oatp1B3 mRNA Has the Potential to Become a Detection and Prognostic Biomarker for Human Colorectal Cancer
    Yuchen Sun, Manami Harada, Osamu Shimozato, Hiroaki Souda, Nobuhiro Takiguchi, Yoshihiro Nabeya, Takehiko Kamijo, Hidetaka Akita, Naohiko Anzai, Kan Chiba, Tomomi Furihata
    Biomarkers in Medicine.2017; 11(8): 629.     CrossRef
  • Screening of colorectal cancer: present and future
    Marcello Maida, Fabio Salvatore Macaluso, Gianluca Ianiro, Francesca Mangiola, Emanuele Sinagra, Georgina Hold, Carlo Maida, Giovanni Cammarota, Antonio Gasbarrini, Giuseppe Scarpulla
    Expert Review of Anticancer Therapy.2017; 17(12): 1131.     CrossRef
  • Age-adapted Variation in Screening Interval of Fecal Immunochemical Test May Improve its Participation and Colonoscopy Acceptance
    Min Seob Kwak, Jae Myung Cha, Jin Young Yoon, Jung Won Jeon, Hyun Phil Shin, Kwang Ro Joo, Joung Il Lee
    Journal of Clinical Gastroenterology.2017; 51(9): 825.     CrossRef
  • Use of a Low Cut-Off Value for the Fecal Immunochemical Test Enables Better Detection of Proximal Neoplasia
    Jae Myung Cha, Joung Il Lee, Kwang Ro Joo, Hyun Phil Shin, Jung Won Jeun, Jun Uk Lim
    Digestive Diseases and Sciences.2013; 58(11): 3256.     CrossRef
  • Performance of the Fecal Immunochemical Test Is Not Decreased by High Ambient Temperature in the Rapid Return System
    Jae Myung Cha, Joung Il Lee, Kwang Ro Joo, Hyun Phil Shin, Jae Jun Park, Jung Won Jeun, Jun Uk Lim, Sang-Hyun Hwang
    Digestive Diseases and Sciences.2012; 57(8): 2178.     CrossRef
  • A comparison of qualitative and quantitative fecal immunochemical tests in the Korean national colorectal cancer screening program
    Mi Jin Park, Kui Son Choi, You Kyoung Lee, Jae Kwan Jun, Hoo-Yeon Lee
    Scandinavian Journal of Gastroenterology.2012; 47(4): 461.     CrossRef
  • Clinical Features of Colorectal Cancer Detected by the National Cancer Screening Program
    Dae-Do Park, Rumi Shin, Ji-Sun Kim, Heung-Kwon Oh, Seung-Yong Jeong, Kyu Joo Park, Jae-Gahb Park
    Journal of the Korean Society of Coloproctology.2010; 26(6): 420.     CrossRef
  • The Significance of Fecal Immunochemical Test to Screen for Colorectal Cancer in National Cancer Screening Program
    Jun Uk Lim, Na Young Bae, Won Koung Song, Jae Myung Cha, Joung Il Lee
    Intestinal Research.2010; 8(2): 126.     CrossRef
  • False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening
    Leo G.M. van Rossum, Anne F. van Rijn, Martijn G.H. van Oijen, Paul Fockens, Robert J.F. Laheij, Andre L.M. Verbeek, Jan B.M.J. Jansen, Evelien Dekker
    International Journal of Cancer.2009; 125(4): 746.     CrossRef
  • Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme
    L G M van Rossum, A F van Rijn, R J F Laheij, M G H van Oijen, P Fockens, J B M J Jansen, A L M Verbeek, E Dekker
    British Journal of Cancer.2009; 101(8): 1274.     CrossRef
  • Random Comparison of Guaiac and Immunochemical Fecal Occult Blood Tests for Colorectal Cancer in a Screening Population
    Leo G. van Rossum, Anne F. van Rijn, Robert J. Laheij, Martijn G. van Oijen, Paul Fockens, Han H. van Krieken, Andre L. Verbeek, Jan B. Jansen, Evelien Dekker
    Gastroenterology.2008; 135(1): 82.     CrossRef
  • 10,882 View
  • 89 Download
  • 30 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP